Algernon Pharmaceuticals Inc (AGNPF)

[GVX808]

“Imagine if Algernon Pharmaceuticals (CSE: AGN) receives FDA Orphan Drug Designation for the use of Ifenprodil as a treatment for IPF. When a company is granted Orphan Drug Designation by the FDA, it is one of the strongest possible catalysts for any biotech stock, especially if the company has a low market cap like AGN currently does with AGN's U.S. OTCQB symbol AGNPF currently trading at a valuation of less than US$10 million!

We have seen many biotech stocks increase by 50%-100% in a single day on record volume on news of receiving FDA Orphan Drug Designation because it grants a potential seven years of market exclusivity after approval!

IPF is a devastating disease where patients lose 2%-5% of their lung function every single month! For 65% of AGN's patients who used Ifenprodil during AGN's recently completed 12-week Phase 2 trial... their lung function either improved or remained stable! Many of AGN's Phase 2 trial participants requested for AGN to provide them with Ifenprodil for them to continue using for their personal use after the trial was completed!”

https://www.inflation.us/content/imagine-if-agn-receives-fda-orphan-drug-designation


- from NIA